Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegenerative Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HSP70/HSPA1A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HSP70/HSPA1A Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. Suitable for ATPase assays and SPR binding studies. |
View HSP70 Products |
| Gene Delivery | HSP70/HSPA1A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View HSP70 Products |
| Benchmark Ab | Anti-HSP70 Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and intracellular flow cytometry. |
View HSP70 Products |
| Validator | HSP70/HSPA1A siRNA Set For target knockdown verification and target validation assays. |
View HSP70 Products |
| Related Target A | HSPA8 (HSC70) Constitutive homolog required for counter-screening to ensure drug selectivity and reduce toxicity. |
View HSPA8 Products |
| Related Target B | HSP90 Synergistic chaperone pathway partner; co-targeting often enhances therapeutic efficacy in oncology. |
View HSP90 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against constitutive HSC70 (HSPA8) | Human HSPA1A and HSPA8 ortholog proteins available with >95% purity for robust comparative screening |
| High-throughput screening (HTS) compatibility | Low-endotoxin, carrier-free recombinant proteins optimized for enzymatic and thermal shift assays |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration |
| False Positives in Phenotypic Screening | Sequence-verified siRNA sets included for target-specific knockdown validation |
Live HSP70/HSPA1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HSP70/HSPA1A therapeutics is intensifying, with major players shifting focus from traditional non-selective inhibitors to highly selective small molecules, allosteric modulators, and PROTACs (Proteolysis Targeting Chimeras). As first-generation therapies reach the clinic, the next wave of R&D is targeting isoform-specific pockets to bypass the systemic toxicity historically associated with pan-HSP inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Academic Spin-offs, Biotech | Oncology, Neurodegeneration | Selectivity Assay (Need Mutant vs WT Proteins & HSPA8 Panel) |
| PROTAC (Degraders) | Arvinas, Kymera (Discovery Phase) | Refractory Solid Tumors | Target Degradation Validation (Need High-Purity Antigen & siRNA) |
| Monoclonal Antibody (Extracellular) | Multivir, apceth Biopharma | Inflammatory Diseases, Oncology | Binding Affinity Validation (Need native-glycosylated HEK293 Proteins) |